Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
1996-10-04
2001-12-04
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S218000, C514S235800, C514S253090, C514S253120, C514S253130, C514S217050, C514S252140, C540S575000, C544S121000, C544S295000, C544S360000, C544S364000, C544S365000
Reexamination Certificate
active
06326371
ABSTRACT:
BACKGROUND
There is an urgent need for efficient drugs in the treatment of mental disorders which are more effective and which have fewer side effects than the drugs in clinical use today. Antipsychotic drugs in current use produce a range of troublesome extrapyratidal movement disorders (e.g. acute dystonic reactions and tardive dyskinesia) and are poor in ameliorating the negative symptoms (e.g. restricted or blunted emotional arousal) of schizophrenia. The main disadvantage of the anti-depressants is that they fail to alleviate depression in 30 to 40% of patients. Anxioltyics are commonly associated with addictive properties.
PRIOR ART
Various pyridyl- and pyrimidyl-piperazine derivates pharmacologically active in the central nervous system are known in the art. Some representative examples can be mentioned. Azaperone, a neuroleptic drug of the butyrophenone series, is a sedative for pigs. Buspirone is an aixiolytic. The anxiolytic effect is thought to be mediated via effects on the 5HT-receptors.
In the U.S. Pat. No. 4,937,245, compounds of the general formula C is disclosed
wherein A is selected from pyridyl or pyrimidyl group, e.g.
wherein preferably R6 is hydrogen and R7 is cyano, amides, methoxy or hydrogen substituent in the 3-position of the pyridyl ring, useful for the treatment of mental disorders such as psychoses, depression and anxiety.
REFERENCES:
patent: 4292321 (1981-09-01), Pattison
patent: 4766215 (1988-08-01), Abou-Gharbia et al.
patent: 4908365 (1990-03-01), Buzas et al.
patent: 4937245 (1990-06-01), Fex et al.
patent: 4994459 (1991-02-01), Butera et al.
patent: 4994460 (1991-02-01), Dextraze et al.
patent: 5177078 (1993-01-01), Ward et al.
patent: 5342839 (1994-08-01), Treiber et al.
patent: 5418236 (1995-05-01), Carmosin et al.
patent: 5432179 (1995-07-01), Kumagai et al.
Saxena,Pharmac. Ther. vol. 66, pp. 339-368 (1995).*
Millan et al.,Journal of Pharmacology and Experimental Theopeuticsvol. 262, p. 451-463.*
Patel et al., Indian Journal of Experimental Biology, vol. 9, No. (1), (Jan. 1971), 117-119.*
Vadodaria et al, J. Med. Chem., vol. 12, pp. 860-865(1969).
Burger, Medical Chemistry, Third Edition, Part I, pp. 74-77 (1970).
Abramo Lisbeth
Brodszki Martin
Lundstedt Torbjorn
Nordvi Curt
Olsson Knut Gunnar
Bernhardt Emily
Fish & Richardson P.C.
Pharmacia Aktiebolag
LandOfFree
Pyrudyl and pyrimidylpiperazine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrudyl and pyrimidylpiperazine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrudyl and pyrimidylpiperazine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2580428